Huda Salah Eldin: The Challenge of Balancing Antithrombotic Therapy After PCI
Huda Salah Eldin, Certified traineer in clinical pharmacy and critical care at Egyption health council at Egyption Health Council, shared a post on LinkedIn:
“One of the most challenging situations we faced in the CCU: balancing antiplatelet therapy and anticoagulation after PCI.
A patient with a recent myocardial infarction (MI) undergoes PCI with stent placement and requires dual antiplatelet therapy (DAPT).
But what if the patient also has an indication for long-term oral anticoagulation, such as atrial fibrillation (AF) or venous thromboembolism requiring extended treatment?
Combining these medications increases bleeding risk-making the choice and duration of therapy crucial.
The 2023 ESC guidelines for acute coronary syndromes outline an approach tailored to each patient’s ischaemic and bleeding risks:
1.Initial phase: Triple therapy
- Oral anticoagulant plus Clopidogrel plus Aspirin
The default duration is up to 1 week. This may be extended to 1 month when the risk of stent thrombosis outweighs the bleeding risk.
2.Next phase: Dual antithrombotic therapy
- Stop Aspirin and continue Oral anticoagulant plus Clopidogrel.
Continue for up to 12 months after the acute event. A shorter duration may be considered in selected patients at high bleeding risk.
3.Beyond 12 months: Anticoagulation alone
- Discontinue Clopidogrel and continue the oral anticoagulant alone in most patients with an ongoing indication.
The goal is always to balance protection against stent thrombosis and thromboembolic events with the risk of bleeding.
An individualised treatment plan – and regular reassessment – makes all the difference.
Which factors most influence your decision about the duration of triple therapy in clinical practice?”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines